Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
about
Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteersTreatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastineRole of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statementBalanced discussion of second-generation antihistamines' data.Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response.A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitisAcute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study.Bilastine: in allergic rhinitis and urticaria.A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled studyCritical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticariaEvaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.The role and choice criteria of antihistamines in allergy management - expert opinion.Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.Safety evaluation of desloratadine in allergic rhinitis.Bilastine for the treatment of urticaria.Emerging therapies in allergic conjunctivitis and dry eye syndrome.Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology.Pharmacotherapy of allergic rhinitis: current options and future perspectives.New therapies for allergic rhinitis.Bilastine: new insight into antihistamine treatment.Current controversies and challenges in allergic rhinitis management.Allergic rhinitis: pharmacotherapy in pregnancy and old age.Rupatadine: global safety evaluation in allergic rhinitis and urticaria.Th17 responses are not altered by natural exposure to seasonal allergens in pollen-sensitive patients.Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria.Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.Oral availability of bilastine.Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine.Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers.Bilastine in allergic rhinoconjunctivitis and urticaria
P2860
Q24563637-D9638C2E-10C1-457C-A5AD-0F16E8F9C30AQ26750723-4D88C663-697E-4BE8-86E5-E9F632AC211EQ26769045-6B443661-32A2-486D-A912-8D85B467BA43Q31150876-BB0E4550-FA96-4324-8C6A-3FD0BDC146FCQ33773999-F22F4960-BABA-4356-A8F8-880C52275B72Q33914193-F3F0FC6E-43DE-4CDF-8E07-2BC583B0FDFBQ34139004-419203F5-07D3-40F8-88B9-1B681D8C3960Q34189947-C1BFB228-7A41-4CF9-8F0C-E9E772CA34E9Q34238984-F1F0AE34-CD73-4B19-80D9-39DF0D1F14E7Q34259088-425950D6-6D93-415C-BEAB-0037B34AA070Q34639105-209BE4B9-4739-4849-A459-DA19252724EDQ36638677-C8D8DC85-2E23-418A-A78D-8AFE651D428FQ36833151-87EB28CC-C5E0-4654-914E-8B9C4493A847Q37115078-5D541E37-B735-4BC1-81A0-4E787EC21BE6Q37531868-5A29DB88-ED6B-4D0B-B3D7-12DFDC99D062Q37914886-5E0A9EAE-3C10-4EA3-80FB-098A5C2D59CEQ38097964-5F0969CC-C5C7-47DC-9CD5-03A21D44A32CQ38107004-C79E67EE-167F-4A52-9EEF-D2CCAE7DC158Q38119024-215A2B55-C9C7-4CCB-B981-02591A5A82F5Q38129435-48C25103-4E69-41C0-BD41-C0E29B151078Q38161991-FC46CAF2-7BC8-4FF3-8040-B6E8C8D76F9FQ38185937-E99E0967-1F03-401D-996E-695F429F2882Q38423124-646F6E54-0D72-4ABF-B233-4D0AC9E67F06Q38577949-23FA7328-C955-4B91-8DBA-D7BDF2FD8B48Q38833851-04FEB89C-581F-4B7E-8AFD-A9E32189617AQ38921694-7F1A7EE5-5AC0-4BC8-95FB-19B54D325F9FQ39229226-371976F7-14C0-44D6-BC83-79F57CDDF0F0Q39280604-27A25036-4EBF-4E56-95E2-B908253106D9Q42052228-81193B7C-AE29-4D2E-A31D-555D4F4ADFEEQ42693919-A8EED18F-F33B-45C5-9F87-1440755E0C9AQ47705701-8EA42501-E070-436C-B043-D6D0B6EC2CBFQ47883741-99219756-A986-4254-B0EA-D0935B2C704DQ53563461-2F3CB12C-8779-42A6-A9BC-4C8617FCF185Q57479825-3215E71F-031D-4AE4-AFD6-D2B3E1A06E45
P2860
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparison of the efficacy and ...... al allergic rhinitis patients.
@ast
Comparison of the efficacy and ...... al allergic rhinitis patients.
@en
Comparison of the efficacy and ...... al allergic rhinitis patients.
@nl
type
label
Comparison of the efficacy and ...... al allergic rhinitis patients.
@ast
Comparison of the efficacy and ...... al allergic rhinitis patients.
@en
Comparison of the efficacy and ...... al allergic rhinitis patients.
@nl
prefLabel
Comparison of the efficacy and ...... al allergic rhinitis patients.
@ast
Comparison of the efficacy and ...... al allergic rhinitis patients.
@en
Comparison of the efficacy and ...... al allergic rhinitis patients.
@nl
P2093
P1433
P1476
Comparison of the efficacy and ...... al allergic rhinitis patients.
@en
P2093
A Loureiro
Bilastine International Working Group
M M Gorina
P van de Heyning
V Dimitrov
P304
P356
10.1111/J.1398-9995.2008.01813.X
P577
2009-01-01T00:00:00Z